


FORM PTO-1390 (Modified) (REV 11-98)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 6386-08-IM	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 09/889341)	
INTERNATIONAL APPLICATION NO. PCT/EP00/01574		INTERNATIONAL FILING DATE 25 February 2000		PRIORITY DATE CLAIMED 30 March 1999	
TITLE OF INVENTION METHOD FOR ARYLATING AZA-HETEROCYCLES WITH ACTIVATED AROMATIC COMPOUNDS IN THE PRESENCE OF CESIUM CARBONATE					
APPLICANT(S) FOR DO/EO/US BARTH, Hubert; STEINER, Klaus; BETCHE, Hans-Jurgen; SCHNEIDER, Simon; BAYER, Ulrich; WESTERMEYER, Manfred; WOLFSPERGER, Ulrike					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input type="checkbox"/> A copy of the International Search Report (PCT/ISA/210). 8. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 9. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 10. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 11. <input type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409). 12. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). <p>Items 13 to 20 below concern document(s) or information included:</p> <ol style="list-style-type: none"> 13. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 15. <input type="checkbox"/> A FIRST preliminary amendment. 16. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 17. <input type="checkbox"/> A substitute specification. 18. <input type="checkbox"/> A change of power of attorney and/or address letter. 19. <input checked="" type="checkbox"/> Certificate of Mailing by Express Mail 20. <input type="checkbox"/> Other items or information: 					

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.52(b)(1))		INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER	
09/889341		PCT/EP00/01574		6386-08-IM	
21. The following fees are submitted:				CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :					
<input checked="" type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO				\$970.00	
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO				\$840.00	
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO				\$690.00	
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4)				\$670.00	
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4)				\$96.00	
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$970.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (c)).				\$0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	5 - 20 =	0	x \$18.00	\$0.00	
Independent claims	2 - 3 =	0	x \$80.00	\$0.00	
Multiple Dependent Claims (check if applicable).			<input checked="" type="checkbox"/>	\$260.00	
TOTAL OF ABOVE CALCULATIONS =				\$1,230.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable).			<input type="checkbox"/>	\$0.00	
SUBTOTAL =				\$1,230.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).			+	\$0.00	
TOTAL NATIONAL FEE =				\$1,230.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).			<input type="checkbox"/>	\$0.00	
TOTAL FEES ENCLOSED =				\$1,230.00	
				Amount to be: refunded	\$
				charged	\$
<input type="checkbox"/> A check in the amount of _____ to cover the above fees is enclosed.					
<input checked="" type="checkbox"/> Please charge my Deposit Account No. 23-0455 in the amount of \$1,230.00 to cover the above fees. A duplicate copy of this sheet is enclosed.					
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. 23-0455 A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:					
Charles W. Ashbrook Registration No. 27,610 Warner-Lambert Company 2800 Plymouth Road Ann Arbor, MI 48105 Tel. (734) 622-5215 Fax (734) 622-1553			 SIGNATURE Charles W. Ashbrook NAME 27,610 REGISTRATION NUMBER 16 July 2001 DATE		

09/889349
RECEIVED # 27
JUL 16 2001
Docket No.

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)

Applicant(s): **Hubert Barth, et al.**

6386-08-IM

Serial No.

Filing Date

Examiner

Group Art Unit

Invention: **METHOD FOR ARYLATING AZA-HETEROCYCLES WITH ACTIVATED AROMATIC COMPOUNDS
IN THE PRESENCE OF CESIUM CARBONATE**

I hereby certify that the following correspondence:

Application for filing under 35 U.S.C. 371

(Identify type of correspondence)

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under
37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231

July 16, 2001

(Date)

Cindy Malocha

(Typed or Printed Name of Person Mailing Correspondence)

Cindy Malocha
(Signature of Person Mailing Correspondence)

EK651646157US

("Express Mail" Mailing Label Number)

Note: Each paper must have its own certificate of mailing.



Rec'd PCT/PTO 22 JUL 2002-6386


09/889341

GÖDECKE AKTIENGESELLSCHAFT

Process for the arylation of aza-heterocycles with activated
aromatics in presence of caesium carbonate


Description


The subject of the invention is a process for the
nucleophilic substitution on activated aromatics of the
general formula XIV





XIV


in which R1, R2, R3, R4 and R5 are the same or different and
signify a hydrogen atom, a nitro group, a cyano group, an
alkoxycarbonyl group with up to 5 C-atoms, an aldehyde group,
an alkylcarbonyl group with up to 5 C-atoms, an arylcarbonyl
group or an amide group, whereby the radicals R1 to R5 cannot
all simultaneously be a hydrogen atom and HAL stands for a
halogen atom but especially for a fluorine atom, with
nucleophils, such as alcohols, amines, sulfoximides,
CH-acidic compounds of the formulae V to XI



 V



 VI


 VII



 VIII


 IX


 X


 XI

The process is preferred for the preparation of compounds of the general formula I




Compounds of the general formula I play an important part in medicinal chemistry. Thus, e.g. one finds the

N-aryl-aza-heterocyclic structure in substances with anti-oestrogenic (E. Angerer, J. Strohmeier, J. Med. Chem. 30, 131, 1987), with analgesic (E.J. Glamkowski et al., J. Med. Chem. 28, 66, 1985), with anti-diabetic (R.B. Chapleo, G.P. Fagan, Ann. Drug 5 Data Rep. 15, 59, 1993), with anti-microbial (A.G. Kamat, G.S. Gadaginamath, Indian J. Chem., Sect. B, 33, 255, 1994), with neuroleptic (J. Perregaard et al., J. Med. Chem. 35, 1092, 1992), with anti-allergic (P. Ungast et al., J. Med. Chem. 32, 1360, 1989), with angiotensin-antagonistic (S.R. Stabler and Jahangir, Syn. Commun. 24, 123, 1994) and with PDGF receptor inhibitory action (Brian D. Palmer et al., J. Med. Chem. 41, 5457, 1998).

Compounds of the general formula I can be prepared according to various methods. A frequently used method consists in the reaction of aza-heterocycles with activated aryl halides in the presence of catalysts and/or bases or, in few cases, also without further additives, according to scheme 1:

Schema 1



Thus, e.g. 1-(benzotriazol-1-yl)-2,4-dinitro-benzene can be obtained in 96% yield by 9 days boiling of benzotriazole in toluene (A.R. Katritzky, J. Wu, Synthesis 1994, 597).

4-Heterocyclicly-substituted nitrobenzenes and benzaldehydes can be obtained by reaction of the particular aza-heterocycles, such as e.g. benzotriazole, 1,2,4-triazole

or benzimidazole, with 4- fluorobenzaldehyde or 4-fluoro- or 4-chlorobenzaldehyde in DMSO or DMF at 100°C (D.J. Gale, J.F.K. Wilshire, Aust. J. Chem. 23, 1063, 1970; J. Rosevear, J.F.K. Wilshire, Aust. J. Chem. 44, 1097, 1991).

Nitrophenylazoles can be prepared by Ullmann condensation of azoles with aryl halides in pyridine in the presence of potassium carbonate and copper (II) oxide at high temperatures and long reaction times (M.A. Khan, J.B. Polys, J. Chem. Soc. (C), 1970, 85; A.K. Khan, E.K. Rocha, Chem. Pharm. Bull. 25, 3110, 1977) or, however, by reaction of azoles with suitable fluoronitrobenzenes in DMSO at comparatively high temperature and in the presence of potassium carbonate (M.F. Mackay, G.J. Trantino, J.F. Wilshire, Aust. J. Chem. 46, 417, 1993).

1-Arylindoles with activating substituents in the aryl part were obtained by reaction of indole with activated aryl halides in the presence of 37% KF/Al₂O₃ and catalytic amounts of crown ethers in DMSO at 120°C (W.J. Smith, J. Scott Sawyer, Tetrahedron Lett. 37, 299, 1996).

There is also described the arylation of azoles with activated aryl halides in the presence of bases, such as caesium carbonate and sodium tert.-butylate, whereby, however, the presence of palladium catalysts is additionally necessary and the reaction itself requires high temperatures (65° to 120°C) and long reaction times (3 to 48 hours) (G. Mann, J.F. Hartwig, M.D. Driver, C. Fernandez-Rivas, J. Am. Chem. Soc. 120, 827, 1998; I.P. Beletskaya, D.V. Davydov, M. MorenoManas, Tetrahedron Lett. 39, 5617, 1998).


The use of caesium carbonate as reagent in the case of carbon-heteroatom coupling reactions is also known but further special catalysts must additionally always be used in

such reactions (Christopher G. Frost, Paul Mendonca, J. Chem. Soc., Perkin Trans. 1, 1998, 2615).

In general, from the above-given examples, it can be deduced that for arylations of azoles with activated aryl halides, relatively drastic conditions, such as high temperatures, long reaction times, as well as special catalysts, are frequently necessary.

In connection with the synthesis of a potentially anti-cancer compound, the reaction was investigated by use of morpholinopropanol (III) with o-nitrofluorobenzene (II) (scheme 2):

Scheme 2




Based on our experience with the system caesium carbonate/dimethylformamide for the preparation of carbonates from alcohols and alkyl/aryl halides (DE 199 05 222.0) and of heterocyclic carbamates from aza-heterocycles and alkyl/aryl halides, we investigated whether this system is also suitable for the above reaction.

Surprisingly, it was found that this reaction leads at 23°C within 48 hours to the desired product (IV) in 82% yield.

On the basis of this finding, it was now investigated whether other nucleophiles, such as e.g. the nucleophiles V to X also react with 2-fluoronitrobenzene at room temperature in the system caesium carbonate/dimethylformamide:

Figure 1



It was found that these reactions also give the desired products in good to very good yield at room temperature within 24 to 64 hours. The reaction of 2,5-difluoronitrobenzene (XII) with malonic acid dimethyl ester (XI) at room temperature in the system caesium carbonate/dimethylformamide also leads after 24 hours in 98% yield to the desired product XIII (scheme 3):


Scheme 3



The preparation of compound XIII is described in the literature with use of sodium hydride in dimethyl sulphoxide

at 100°C in 96% yield (Li Sun et al., J. Med. Chem. 41, 2588, 1998).


Encouraged by these results, the arylation of aza-heterocycles with activated aromatics of the general formula XIV



XIV

in which R¹ to R⁵ have the above-given meaning and HAL stands for a halogen atom but especially for a fluorine atom, was investigated in the system caesium carbonate/dimethylformamide.

Surprisingly, it was found that almost all azaheterocycles used already react at room temperature in the presence of caesium carbonate/dimethylformamide with activated fluoroaromatics of the general formula XV to give compounds of the general formula I



XV

Instead of dimethylformamide, there can also be used other dipolar aprotic solvents, such as e.g. dimethylacetamide, acetonitrile, dimethylsulphoxide, acetone or

N-methylpyrrolidone; however, the reaction times at room temperature are then distinctly longer and the yields often lower.

The process procedure in the case of the preparative carrying out of the arylation is very simple. One dissolves equimolar amounts of azaheterocycle and activated aromatics of the general formula XIV but especially of the general formula XV at room temperature in a suitable dipolar aprotic solvent, especially dimethylformamide, adds thereto a 2 to 4 molar excess of anhydrous caesium carbonate and stirs at room temperature until the reaction is ended. The reaction is monitored by means of thin layer chromatography. In the case of less reactive aromatics, in a few cases the reaction temperature must be increased to about 80°C.

At the end of the reaction, one pours the suspension on to water, extracts the product with ethyl acetate and purifies the product obtained after evaporation of the organic phase with the methods usual in organic chemistry, e.g. by crystallisation or chromatography.

The invention is illustrated and explained by the following embodimental examples:

Example 1

2-Morpholinopropyloxynitrobenzene

0.57 g 2-fluoronitrobenzene, 0.65 g morpholino-propanol., 3.0 g caesium carbonate and 30 ml dimethylformamide are stirred for 2 days at room temperature in a closed 50 ml round-bottomed flask. One pours the suspension on to 50 ml water, extracts the aqueous phase 3 times with, in each case, 50 ml ethyl acetate and evaporates the combined organic phases on a rotavapor. For the removal of the dimethylformamide, which would disturb the chromatographic

separation, the DMF-containing residue is again evaporated 2 to 3 times, together with some toluene, at 50°C and 30 mbar vacuum. The oily residue is then purified on silica gel (0.04 to 0.063 mm) at 0.1 bar by flash chromatography. One obtains 0.9 g of oil (82.4%).

The following Examples were carried out analogously to Example 1, there are given the following reaction parameters (reaction time/eluent for chromatography/yield/physical statements):

Example 2

2-Dimethylaminoethyloxynitrobenzene
from 2-fluoronitrobenzene and 2-dimethylaminoethanol
64 h/toluene-ethanol 10+2/91.8%/oil

Example 3

2-Dimethylaminopropyloxynitrobenzene
from 2-fluoronitrobenzene and 3-dimethylaminopropanol-
h/methylene chloride-methanol
10 + 2/58.7%/oil

Example 4

2-(3,3-Diethoxypropoxy)-nitrobenzene
from 2-fluoronitrobenzene and 3-hydroxypropionaldehyde
diethyl acetal
64 h/hexane-ethyl acetate 10+2/83.7%/oil

Example 5

2-Benzyloxynitrobenzene
from 2-fluoronitrobenzene and benzyl alcohol
24 h/toluene/95.7%/oil

Example 6

2-Benzylaminonitrobenzene

from 2-fluoronitrobenzene and benzylamine
64 h/hexane-ethyl acetate 10+2/42.7%/m.p. 74°C

Example 7

4-Fluoro-2-nitrophenylmalonic acid dimethyl ester from
2,5-difluoronitrobenzene and malonic acid dimethyl ester
24 h/toluene-ethanol 10+0.5/98%/oil

Example 8

N-2-Nitrophenyldiphenyl sulphoximide
from 2-fluoronitrobenzene and diphenyl sulphoximide
48 h/toluene-ethanol 10+2/72%/m.p. 158°C

Example 9

N-2-cyanophenyldiphenyl sulphoximide
from 2-fluorobenzonitrile and diphenyl sulphoximide at 80°C
8 h/toluene-ethanol 10+1/74.3%/m.p. 160°C

Example 10

N-4-Cyanophenyldiphenyl sulphoximide
from 4-fluorobenzonitrile and diphenyl sulphoximide
64 h/toluene-ethanol 10+1/61.2%/m.p. 159°C

Example 11

N-4-Nitrophenyldiphenyl sulphoximide
from 4-fluoronitrobenzene and diphenyl sulphoximide
64 h/toluene-ethanol 10 + 0.5/64.1%/m.p. 166°C

Example 12

1-(2-Nitrophenyl)-indole
from 2-fluoronitrobenzene and indole
24 h/hexane-ethyl acetate 10+2/90%/81°C

Example 13

1-(4-Cyanophenyl)-pyrrole

Example 14

Example 15

Example 16

Example 17

Example 18

Example 19

Example 20

Example 21

Example 22

Example 23

Example 24

Example 25

Example 26

1-(2-Methoxycarbonylphenyl)-indole
from 2-fluorobenzoic acid methyl ester and indole at 80°C
8 h/hexane-ethyl acetate 10+2/19.4%/oil

5-Methyl-1-(4-nitrophenyl)-indole
from 4-fluoronitrobenzene and 5-methylindole
24 h/toluene/77.3%/m.p. 147°C

5-Nitro-1-(4-nitrophenyl)-indole
from 4-fluoronitrobenzene and 5-nitroindole
24 h/crystallisation in the case of working up/86.9%/m.p.
235°C

5-Chloro-1-(2-nitrophenyl)-indole
from 2-fluoronitrobenzene and 5-chloroindole
24 h/toluene/71.5%/m.p. 142°C

5-Methoxy-L-(2-cyanophenyl)-indole
from 2-fluorobenzonitrile and 5-methoxyindole
3 h/toluene/100%/m.p. 99°C

1-(2-Nitrophenyl)-pyrrole
from 2-fluoronitrobenzene and pyrrole
64 h/hexane-ethyl acetate 10+2/68.6%/m.p. 105°C

5-Methoxy-1-(4-nitrophenyl)-indole
from 4-chloronitrobenzene and 5-methoxyindole at 80°C
8 h/toluene/27.2%/m.p. 187°C

3-Methyl-1-(4-nitrophenyl)-indole
from 4-fluoronitrobenzene and 3-methylindole
24 h/toluene/84.1%/m.p. 146°C

Example 34

5-Methoxy-1-(4-ethoxycarbonylphenyl)-indole
from 4-fluorobenzoic acid ethyl ester and 5-methoxyindole at
80°C
8 h/hexane-ethyl acetate 10 + 2/68.5%/oil

Example 35

5-Methoxy-1-(4-nitrophenyl)-indole
from 4-fluoronitrobenzene and 5-methoxyindole
18 h/crystallisation in the case of working up/88.1%/ 5 m.p.
188°C

Example 36

1-(2-Nitrophenyl)-indole-2-carboxylic acid ethyl ester
from 2-fluoronitrobenzene and indole-2-carboxylic acid ethyl
ester
58 h/toluene/47.9%/m.p. 90°C

Example 37

1-(4-Nitrophenyl)-indole-2-carboxylic acid ethyl ester
from 4-fluoronitrobenzene and indole-2-carboxylic acid ethyl
ester at 80°C
8 h/toluene/78.5%/m.p. 135°C

Example 38

1-(3-Nitrophenyl)-indole from
3-fluoronitrobenzene and indole at 80°C
6 h/hexane-ethyl acetate 10+2/72.9%/m.p. 66°C

Example 39

1-(3-Cyanophenyl)-indole
from 3-fluorobenzonitrile and indole at 80°C
8 h/toluene-ethanol 10+1/55.8%/m.p. 37°C

Example 40

1-(2-Cyanophenyl)-indole

from 2-fluorobenzonitrile and indole

64 h/toluene/100%/m.p. 112°C

Example 41

1-(2-Nitrophenyl)-imidazole

from 2-fluoronitrobenzene and imidazole

18 h/toluene-ethanol 10+2/92%/m.p. 98° - 99°C

Example 42

1-(2-Nitrophenyl)-benzimidazole

from 2-fluoronitrobenzene and benzimidazole

18 h/toluene-ethanol 10+2/98.8%/oil

Example 43

1-(4-Nitrophenyl)-indazole

from 4-fluoronitrobenzene and indazole

18 h/crystallisation in the case of working up/92%/ m.p.

166°C

Example 44

N-2,4-Dibitrophenylcarbazole

from 2,4-dinitrofluorobenzene and carbazole

18 h/crystallisation in the case of working up/m.p. 189°C

Example 45

1-(2-Cyanophenyl)-1,2,3-triazole

from 2-fluorobenzonitrile and 1,2,3-triazole

24 h/toluene-ethanol 10+1/14.2%/m.p. 112°C

Example 46

4-(4-Cyanophenyl)-1,2,4-triazole

from 4-fluorobenzonitrile and 1,2,4-triazole

24 h/toluene-ethanol 10+2/14.2%/m.p. 169°C

Example 47

5-Chloro-1-(2-cyanophenyl)-indole

from 2-fluorobenzonitrile and 5-chloroindole

2 h/toluene/70.4%/m.p. 129 - 130°C

Example 48


1-(2-Pyridyl)-indole

from 2-fluoropyridine and indole at 80°C

24 h/toluene/84.1%/m.p. 58°C.








Patent Claims

1. Process for the nucleophilic substitution on activated aromatics of the general formula XIV




in which R1, R2, R3, R4 and R5 are the same or different and signify a hydrogen atom, a nitro group, a cyano group, an alkoxycarbonyl group with up to 5 C atoms, an aldehyde group, an alkylcarbonyl group with up to 5 C-atoms, an arylcarbonyl group or an amide group, whereby the radicals R1 to R5 cannot all simultaneously be a hydrogen atom and HAL stands for a halogen atom, with nucleophils, such as alcohols, amines, sulphoxides, CH-acidic compounds of the formulae V to XI

Figure1



in dipolar aprotic solvents in the presence of caesium carbonate at room temperature.

2. Process according to claim 1 for the preparation of compounds of the general formula I




in which HETN signifies an aromatic aza-heterocycle with, in all, 5 or 6 ring atoms, whereby up to 3 ring atoms can be nitrogen atoms and up to two further aromatic carbon rings can be condensed on to the heterocycle and R1, R2, R3, R4 and R5 have the above given meaning.

3. Process according to claim 1 or 2, characterised in that the solvent is acetone, acetonitrile, dimethylsulphoxide, dimethylacetamide, N-methylpyrrolidone or dimethylformamide.
4. Process according to claim 1 or 2, characterised in that the solvent is dimethylformamide.
5. Process according to claim 1 or 2, characterised in that HAL in the general formula XIV is a fluorine atom.

Summary

The invention concerns a process for the preparation of N-aryl-aza-heterocycles of the general formula I



by reaction of aza-heterocycles with activated aryl halides with use of caesium carbonate without addition of further catalysts at room temperature.

Docket No.
6386-08-IM

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

METHOD FOR ACYLATING AZA-HETEROCYCLES WITH ACTIVATED AROMATIC COMPOUNDS
IN THE PRESENCE OF CESIUM CARBONATE

the specification of which

(check one)

☒ is attached hereto.

☐ was filed on _____ As United States Application No. _____ or PCT International
Application Number _____
and was amended on _____
(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Applications

Priority Not Claimed

19914610.1 Germany 30MR1999
(Number) (Country) (Day/Month/Year Filed)

☐

(Number) (Country) (Day/Month/Year Filed)

☐

(Number) (Country) (Day/Month/Year Filed)

☐

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

PCT/EP00/01574
(Application Serial No.)

25FE2000
(Filing Date)

pending
(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)

Charles W. Ashbrook 27,610
 Heidi Berven P-48,951
 Evan J. Federman 37,060
 Mehdi Ganjeizadeh 47,585
 Suzanne M. Harvey 42,640
 David R. Kurlandsky 41,505

Darryl C. Little 40,703
 J. Trevor Lumb 28,567
 Claude F. Purchase 47,871
 Francis J. Tinney 33,069
 Linda Vag 32,071

Send Correspondence to: Charles W. Ashbrook
Warner-Lambert Company
2800 Plymouth Road
Ann Arbor, Michigan 48105

Direct Telephone Calls to: (name and telephone number)
 Charles W. Ashbrook (734) 622-5215

Full name of sole or first inventor	<u>Hubert Barth</u>	
Sole or first inventor signature	<u>Hubert Barth</u>	Date <u>06/25/01</u>
Residence	<u>Emmendingen, Germany</u>	
Citizenship	<u>Germany</u>	
Post Office Address	<u>Bertolt-Brecht-Weg 6</u> <u>D-79312 Emmendingen, Germany</u>	

Full name of sole or second inventor	<u>Klaus Steiner</u>	
Sole or second inventor signature	<u>Klaus Steiner</u>	Date <u>06/29/01</u>
Residence	<u>Emmendingen, Germany</u>	
Citizenship	<u>Germany</u>	
Post Office Address	<u>Jörg-Erb-Weg 6</u> <u>D-79312 Emmendingen, Germany</u>	

Full name of sole or third inventor

Simon Schneider

Sole or third inventor signature

Date

06/28/01

Residence

Merzhausen, Germany

Citizenship

Germany

Post Office Address

Alte Strasse 28A

79249 Merzhausen, Germany

Full name of sole or fourth inventor

Ulrich Bayer

Sole or fourth inventor signature

Date

06/25/01

Residence

Ulm, Germany

Citizenship

Germany

Post Office Address

Weickmannstrasse 25

89077 Ulm, Germany

Full name of sole or fifth inventor

Manfred Westermayer

Sole or fifth inventor signature

Date

06/25/01

Residence

Gundelfingen, Germany

Citizenship

Germany

Post Office Address

Kandelstrasse 62

79194 Gundelfingen, Germany

Full name of sole or sixth inventor

Ulrike Wolfspurger

Sole or sixth inventor signature

Ulrike Wolfspurger

Date

06/25/01

Residence

Gundelfingen, Germany

Citizenship

Germany

Post Office Address

Gewerbestrasse 84

79194 Gundelfingen, Germany

Full name of sole or seventh inventor

Hans-Jürgen Betsche

Sole or seventh inventor signature

Hans Jürgen Betsche

Date

06/25/01

Residence

Vörstetten, Germany

Citizenship

Germany

Post Office Address

Im Gottesacker 8

79279 Vörstetten, Germany